Tirzepatide Benefits: What Studies Report

How this page frames the evidence

The word "benefits" is used loosely in general conversation. In the published literature, what exists is a set of trials with defined populations, defined durations, defined endpoints, and reported directions of effect. This page organizes those reports by outcome domain. Nothing here is a claim that tirzepatide will do anything for any individual, and nothing here is a recommendation. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication, or treatment decision.

Every finding below carries the PubMed link for the study that reported it in the same sentence. Where evidence is preclinical or laboratory-based, it is labeled as such. Where people commonly assume a benefit that the cited literature did not test, that absence is stated plainly rather than filled in.

Receptor pharmacology: what laboratory work described

Before the clinical program, pharmacology work characterized tirzepatide as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, and described its signaling as imbalanced and biased rather than equivalent at both receptors (PMID 32730231). That work was receptor- and cell-level pharmacology, not a clinical outcome trial, and researchers in that report did not measure weight, glycemia, or any patient outcome (PMID 32730231).

Outcome domains at a glance

Body weight in adults without diabetes

SURMOUNT-1 randomized adults with obesity, or overweight with at least one weight-related complication and without diabetes, to weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks, and researchers reported mean weight changes of about −15.0%, −19.5% and −20.9% across the three doses compared with about −3.1% with placebo (PMID 35658024). The study measured percent change in body weight as its co-primary endpoint alongside the proportion of participants reaching a 5% threshold (PMID 35658024).

A separate randomized trial in Chinese adults with obesity, SURMOUNT-CN, administered 10 mg and 15 mg weekly over 52 weeks and reported greater reductions in body weight with both doses than with placebo (PMID 38819983). That trial is relevant because trial populations differ by region, body-size distribution and background care, and the researchers examined this specific population rather than extrapolating (PMID 38819983).

What happened when treatment stopped

SURMOUNT-4 used a randomized-withdrawal design: participants took maximum tolerated tirzepatide (10 mg or 15 mg) during a 36-week open-label lead-in, then were randomized to continue or to switch to placebo for 52 weeks, and the study reported roughly 20.9% mean weight reduction during the lead-in phase (PMID 38078870). Over the randomized phase, researchers reported an additional mean reduction of about 5.5% among those who continued, compared with a mean regain of about 14.0% among those switched to placebo (PMID 38078870). That contrast is the reason weight outcomes in this literature are usually described as treatment-dependent rather than permanent.

Body weight in adults with type 2 diabetes

SURMOUNT-2 enrolled adults with obesity and type 2 diabetes and randomized them to 10 mg or 15 mg weekly or placebo for 72 weeks, and the study reported mean weight reductions of roughly 13% and 15% respectively versus roughly 3% with placebo (PMID 37385275). Weight outcomes in people with type 2 diabetes have historically been smaller than in people without diabetes across incretin trials, and this trial was designed specifically to measure that population rather than assume it (PMID 37385275).

Glycemic measures

SURPASS-1, a double-blind phase 3 trial, gave tirzepatide 5 mg, 10 mg or 15 mg weekly as monotherapy versus placebo for 40 weeks in adults with type 2 diabetes inadequately controlled by diet and exercise, and researchers reported greater reductions in HbA1c and in body weight with all three doses than with placebo (PMID 34186022). That was a monotherapy setting in a drug-naive population, which is narrower than the broader treated diabetes population (PMID 34186022).

Progression to type 2 diabetes

An extension of the SURMOUNT-1 population followed adults with obesity and prediabetes for 176 weeks and reported a markedly lower rate of progression to type 2 diabetes with tirzepatide than with placebo, alongside sustained weight reduction (PMID 39536238). The study measured time to onset of type 2 diabetes as an endpoint over that period; it did not establish what happens to glycemic status after treatment ends (PMID 39536238).

Obstructive sleep apnea

SURMOUNT-OSA comprised two 52-week randomized trials in adults with moderate-to-severe obstructive sleep apnea and obesity — one in participants not using positive airway pressure and one in participants using it — with tirzepatide titrated to a maximum tolerated dose of 10 mg or 15 mg weekly (PMID 38912654). Researchers reported reductions in the apnea-hypopnea index of roughly 25 and 29 events per hour in the tirzepatide groups versus roughly 5 events per hour with placebo across the two trials (PMID 38912654). AHI was the primary endpoint, so the study measured a polysomnographic outcome rather than, for example, long-term cardiovascular events in sleep apnea (PMID 38912654).

Heart failure with preserved ejection fraction

The SUMMIT trial randomized adults with HFpEF and obesity to tirzepatide titrated up to 15 mg weekly or placebo, and over a median follow-up of about 104 weeks researchers reported a lower risk of the composite of cardiovascular death or a worsening heart-failure event, with a hazard ratio of approximately 0.62 (PMID 39555826). The study also reported improvement in health status measured by the Kansas City Cardiomyopathy Questionnaire clinical summary score compared with placebo (PMID 39555826).

Liver: metabolic dysfunction-associated steatohepatitis

A phase 2 randomized trial in adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis compared tirzepatide 5 mg, 10 mg and 15 mg weekly with placebo over 52 weeks and reported resolution of steatohepatitis without worsening of fibrosis in a larger proportion of tirzepatide-treated participants than placebo-treated participants (PMID 38856224). Researchers described that trial as phase 2, meaning it was sized for histologic endpoints rather than for clinical liver outcomes such as decompensation or mortality (PMID 38856224).

Head-to-head comparison

SURMOUNT-5 randomized adults with obesity and without diabetes to maximum tolerated tirzepatide or maximum tolerated semaglutide for 72 weeks, and the study reported mean weight reduction of about 20.2% with tirzepatide versus about 13.7% with semaglutide (PMID 40353578). That comparison addressed percent weight change; it was not designed as a comparison of cardiovascular or other clinical outcomes (PMID 40353578).

Cardiovascular outcomes: what has and has not been reported here

SURPASS-CVOT was set up to compare tirzepatide with dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease, and the publication cited here described the trial design and baseline characteristics rather than outcome results (PMID 37758044). Readers encountering "tirzepatide protects the heart" framing should note that the design paper reported no event results, and that the HFpEF findings above came from a separate trial in a different population (PMID 39555826).

Claimed benefits the cited literature did not test

Several commonly searched claims are not addressed by the trials cited on this page. None of these studies reported outcomes for longevity or biological aging, cognition or neuroprotection, alcohol or nicotine use, polycystic ovary syndrome or fertility, athletic performance, or skin and hair outcomes. Where a trial measured nothing on a topic, the honest statement is that the evidence is absent from this citation set — not that an effect was ruled out, and not that one exists. Body-composition questions, including how much of the reported weight change was lean mass, are also outside what these cited reports characterized; the weight endpoints described above were percent change in total body weight (PMID 35658024).

Adverse Events: What Studies Report

Across the obesity program, researchers reported that the most common adverse events were gastrointestinal — nausea, diarrhea, vomiting and constipation — and that these were mostly mild to moderate and occurred primarily during dose escalation (PMID 35658024). SURPASS-1 similarly reported gastrointestinal events as the most frequent adverse events with tirzepatide monotherapy over 40 weeks (PMID 34186022), and the sleep apnea trials reported gastrointestinal events as the most common adverse events over 52 weeks (PMID 38912654). Discontinuation due to adverse events was reported in a minority of participants in the 72-week obesity trial (PMID 35658024). Trial safety populations are selected and monitored, so adverse-event rates from these studies describe those trial conditions rather than unsupervised use.

How to read this body of evidence

• Population matters. Weight results in adults with type 2 diabetes (PMID 37385275) differed from those in adults without diabetes (PMID 35658024).
• Endpoint matters. A polysomnographic index (PMID 38912654), a histologic endpoint (PMID 38856224) and a clinical event composite (PMID 39555826) are not interchangeable forms of evidence.
• Duration matters. Trials here ranged from 40 weeks (PMID 34186022) to 176 weeks (PMID 39536238).
• Continuation matters. The randomized-withdrawal design reported regain after switching to placebo (PMID 38078870).

Tirzepatide is a prescription medicine in the jurisdictions where it is approved, and approvals are tied to specific indications and labeling. Research-use-only material is not the same as an approved product and is not intended for human use. This page summarizes published findings and is not medical, legal or regulatory advice.

References

• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)
• Tirzepatide Once Weekly for the Treatment of Obesity (New England Journal of Medicine, 2022)
• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (Lancet, 2023)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2024)
• Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial (JAMA, 2024)
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (New England Journal of Medicine, 2024)
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (New England Journal of Medicine, 2024)
• Tirzepatide for Obesity Treatment and Diabetes Prevention (New England Journal of Medicine, 2025)
• Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (New England Journal of Medicine, 2025)
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (New England Journal of Medicine, 2025)